



Lunit INSIGHT MMG

AI Solution for Mammography






200⁺
Reference Sites

80⁺
Countries Worldwide

7M⁺
*Images Analyzed
(for clinical and research use)*

Breast cancer is
no longer tricky to find.
with AI.



What does Lunit INSIGHT MMG analyze on mammograms?


Lunit INSIGHT MMG detects breast cancer on mammograms with 96% accuracy.

96%
Detects breast cancer
with 96% accuracy

Lunit INSIGHT MMG generates


Detected Location

The location information of detected breast cancer in the form of heatmap and outlines




Abnormality Score

An abnormality score for each side of the breast, which reflects the AI's calculation of the actual presence of the detected breast cancer



Density Assessment

Assessment of breast density, categorized into four types



What are the major benefits of using it?

Detect more breast cancers.

Fast triage of normal cases.

Improved reading performance of general radiologists.

01

Detect more breast cancers

The combination of first-reader radiologists and Lunit AI detects more breast cancers, than not only the first-reader and second-reader radiologists but also the double reading by radiologists.¹

Health check-up centers

Community hospitals and clinics

Radiology departments

02

Fast triage of normal cases

According to the abnormality scores generated by AI, radiologists can successfully triage up to 60% of the entire cases without human interpretation, which can reduce their workload by more than half in mammogram interpretation.²

Health check-up centers

Imaging clinics

Teleradiology centers

60%
*Triage 60% of the entire cases
without human interpretation*

03

Improved reading performance of general radiologists

General radiologists can use the AI analysis results to improve their reading performance, at a level up to that of breast specialists.³

Health check-up centers

Community hospitals and clinics

Radiology departments

Early diagnosis of breast cancer.

Support for decision-making on BI-RADS 3 and 4 cases.

Improved diagnostic accuracy for dense breasts.

04

Early diagnosis of breast cancer

Radiologists can detect T1 and node-negative breast cancer with 91% and 87% accuracy, respectively.⁴

Health check-up centers

Community hospitals and clinics

Radiology departments

91%
AI detection accuracy
of T1 breast cancer

87%
AI detection accuracy of
node-negative cancer

05

Support for decision-making on BI-RADS 3 and 4 cases

For difficult cases classified as BI-RADS 3 or 4, radiologists can compare their reading result and decide with confidence for additional exams such as ultrasound and biopsy.

Health check-up centers

Community hospitals and clinics

Radiology departments

06

Improved diagnostic accuracy for dense breasts

Radiologists can improve their diagnostic accuracy for dense and fatty breasts by up to 9% and 22%, respectively.⁵

Health check-up centers

Community hospitals and clinics

Radiology departments

9%
Dense breast cancer diagnosis
increased by 9% with AI.

22%
Dense breast cancer diagnosis
increased by 22% with AI.

What do the medical journals say?


Below are highlights from the studies published in peer-reviewed journals that validate the performance of Lunit INSIGHT MMG and its clinical value in mammography interpretation.

JAMA Oncology THE LANCET Digital Health

**Accurate
and efficient
diagnosis
boosted with AI**


HIGHLIGHT 1

Improved reading performance of general radiologists and breast specialists.⁶




HIGHLIGHT 2

Detect early breast cancer such as T1 and node-negative breast cancer.⁷



Simulated Triage Workflow

This simulation features a triage workflow model, of which the AI score functions as a supportive information, that reduces radiologists' reading volume and complements their interpretations.



HIGHLIGHT 3

Triage 60% of the entire cases without missing any breast cancer.⁸

RULE OUT

60% of the entire cases with scores below a rule-out threshold could be triaged to a no radiologist work stream and interpreted as negative without missing any screen-detected cancer.

HIGHLIGHT 4


Detect more cancer cases originally interpreted by double reading as normal.⁹

RULE IN

Cases interpreted as normal but with scores above a rule-in threshold could be considered for supplementary breast imaging tests to detect more cancer that could have been missed.

HIGHLIGHT 5


Lunit best detects breast cancer compared to other commercial AI solutions.¹⁰



<Best Performance In Breast Cancer Detection Compared With Other AI Solutions>

HIGHLIGHT 6


Highest sensitivity when combined with first-reader radiologist.¹¹



<Highest Sensitivity When Combined With First-Reader Radiologists>

What do the medical journals say about AI-powered mammography?


Go to Video [→](#)



Five-year survival rate when detected early by AI

96% When Detected Early By AI (stage 1-2)

65% When Missed (stage 3-4)



Reference : AJCC 8th Edition


Lunit INSIGHT successfully analyzed the mammogram of a 59-year-old female patient, detecting breast cancer that had been missed since 2 years ago.

2008

2009

2010

Sample Cases




CASE 1

Biopsy proven cancer

Fine pleomorphic microcalcifications detected in the left breast.

L 85% Abnormality Score




CASE 2

Biopsy proven cancer

Typical mass with microcalcifications detected in the right breast.

R 99% Abnormality Score



CASE 3

Negative, confirmed by follow-up images

LOW Abnormality Score

Try Lunit AI Solution

Visit insight.lunit.io and upload a DICOM file you have. You will get the AI result within seconds.

Go to page [→](#)



Reference

☰ User Benefits

- ¹ Mattie Salim, Erik Wåhlin, Karin Dembrower, et al. External Evaluation of 3 Commercial Artificial Intelligence Algorithms for Independent Assessment of Screening Mammograms. *JAMA Oncology*. 2020
- ² Karin Dembrower, Erik Wåhlin, et al. Effect of artificial intelligence-based triaging of breast cancer screening mammograms on cancer detection and radiologist workload: a retrospective simulation study. *THE LANCET Digital Health*. 2020
- ^{3,4,5} Hyo-Eun Kim, Hak Hee Kim, et al. Changes in cancer detection and false-positive recall in mammography using artificial intelligence: a retrospective, multireader study. *THE LANCET Digital Health*. 2020

☰ Clinical Validation

- ⁶ Hyo-Eun Kim, Hak Hee Kim, et al. Changes in cancer detection and false-positive recall in mammography using artificial intelligence: a retrospective, multireader study. *THE LANCET Digital Health*. 2020
- ⁷ Hyo-Eun Kim, Hak Hee Kim, et al. Changes in cancer detection and false-positive recall in mammography using artificial intelligence: a retrospective, multireader study. *THE LANCET Digital Health*. 2020
- ^{8,9} Karin Dembrower, Erik Wåhlin, et al. Effect of artificial intelligence-based triaging of breast cancer screening mammograms on cancer detection and radiologist workload: a retrospective simulation study. *THE LANCET Digital Health*. 2020
- ^{10,11} Mattie Salim, Erik Wåhlin, Karin Dembrower, et al. External Evaluation of 3 Commercial Artificial Intelligence Algorithms for Independent Assessment of Screening Mammograms. *JAMA Oncology*. 2020

Research Partners

We welcome research partnerships and other collaboration with medical institutions, healthcare providers, and companies interested in implementing our software products. Currently, we have over 30 worldwide research partners throughout USA, Canada, UK, Sweden, China, and Korea.

Distribution Partners

FUJIFILM



AGFA 

SECTRA



CE 2797

This document is for use by healthcare professionals only. The radiologist should always rely on his own clinical and professional opinion when deciding whether to use a certain product to diagnose or treat a patient.

Not all Lunit products may be available in all markets, as availability is based on the medical and/or regulatory practices of each market. Contact your Lunit representative if you have questions about the availability of the Lunit products in your area.

Lunit Inc. owns, uses or enforces the following trademarks or service marks: Lunit, Lunit INSIGHT MMG. The products described are CE-marked in accordance with applicable EU standards and directives. The product fulfils the requirements for CE marking.

Lunit Inc. 15 Floor, 27 Teheran-ro 2-gil, Gangnam-gu, Seoul, 06241, Republic of Korea

FDA clearance expected in 2021

Document number: MMG-BR-TB-EN_Ver.1

Contact us

General - contact@lunit.io

Investment - ir@lunit.io

Media - media@lunit.io

Partnership - partner@lunit.io

Office

Seoul HQ

Boston, USA

Amsterdam, The Netherlands

Shanghai, China

AI Vision, Earlier Action

Contact Us

Please feel free to email us about any inquiries or questions.

E-mail : contact@lunit.io

Website : www.lunit.io